Compliance with stimulant medications in patients with narcolepsy

Sleep

Volumn 20, Issue 1, 1997, Pages 28-33

  Rogers, Ann E ^a   Aldrich, Michael S ^a   Berrios, Alita M ^a   Rosenberg, Richard S ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b EVANSTON HOSPITAL   (United States)

Author keywords

Compliance; Narcolepsy; Stimulant medications; Treatment

Indexed keywords

CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; METHAMPHETAMINE; METHYLPHENIDATE; PEMOLINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; MALE; NARCOLEPSY; PATIENT COMPLIANCE; PATIENT MONITORING; POLYSOMNOGRAPHY; PRIORITY JOURNAL; SLEEP DISORDER; TREATMENT OUTCOME;

EID: 0030903854     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/20.1.28     Document Type: Article

References (41)

1. Mitler MM. Evaluation of treatment with stimulants in narcolepsy. Sleep 1994;17:5103-6.
2. Mitler MM, Hajdukovic R, Erman MK. Treatment of narcolepsy with methamphetamine. Sleep 1993;16:306-17.
3. Billiard M, Besset A, Montplaisir J, et al. Modafinil: a double-blind multicentric study. Sleep 1994;17:S107-12.
4. Rogers AE, Aldrich MS, Caruso CC. Patterns of sleep and wakefulness in treated narcoleptic subjects. Sleep 1994;17:590.
5. Parkes D. Introduction to the mechanism of action of different treatments of narcolepsy. Sleep 1994;17:S93-6.
6. Mitler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy and its treatment with stimulants. Sleep 1994;17:352-71.
7. Parkes JD. Sleep and its disorders. London: WB Saunders Co., 1985.
8. Billiard M, Picard E, Besset A, Maurel A. Treatment of narcolepsy-cataplexy with modafinil, an alpha-1 adrenoceptor agonist. Sleep Res 1987;16:307.
9. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiat 1988;12:695-700.
10. Laffont F, Cathala HP, Waisbord P, Kohler F. Effects of modafinil on narcoleptic patients. Double-blind crossover study. 9th European Congress of Sleep Research, Jerusalem, 1988:214.
11. Schumacher A, Merritt SL, Cohen FL. The relationship between symptom severity and drug effectiveness as perceived by patients with narcolepsy. Sleep Res 1993;22:263.
12. Sleator EK. Measurement of compliance. Psychopharmacol Bull 1985;21:1089-93.
13. Vander Stichele R. Measurement of patient compliance and the interpretation of randomized clinical trials. Eur J Clin Pharmacol 1991;41:27-35.
14. Simons MR. Nursing interventions related to compliance. Nurs Clin Am 1992;27:477-85.
15. Kauffman RE, Smith-Wright D, Reese CA, Simpson R, Jones F. Medication compliance in hyperactive children. Pediat Pharmacol 1981;1:231-7.
16. Firestone P. Factors associated with children's adherence to stimulant medications. Am J Orthopsychiat 1982;52:447-57.
17. Urquhart J. Variable patient compliance in ambulatory trials -nuisance, threat, opportunity. J Antimicrobial Chemother 1993; 32:643-9.
18. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-7.
19. Eraker SA, Kirscht JP, Becker MD. Understanding and improving patient compliance. Ann Intern Med 1984;100:258-68.
20. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984;6:592-9.
21. Sackett DL, Haynes RB, Tugwell P. Clinical epidemiology: a basic science for clinical medicine. Boston: Little, Brown, 1985: 199.
22. Trostle J. Doctors' orders and patients' self-interest: two views of medication usage? Epilepsy Res Suppl 1988;1:57-69.
23. Pullar T, Birtwell AJ, Wiles PG, Hay A, Feely MP. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin Pharm Ther 1988;44:540-5.
24. Bond WS, Hussar DA. Detection methods and strategies for improving medication compliance. Am J Hosp Pharm 1991;48: 1978-88.
25. Wright EC. Non-compliance - or how many aunts has Matilda? Lancet 1993;342:909-13.
26. Schweizer RT, Rovelli M, Palmeri D, Vossler E, Hull D, Bartus S. Noncompliance in organ transplant recipients. Transplantation 1990;49:374-7.
27. Lima J, Nazarian L, Charney E, Lahti C. Compliance with short-term antimicrobial therapy: some techniques that help. Pediatrics 1976;57:383-6.
28. Cadieux RJ, Kales JD, Kales A, Biever J, Mann LD. Pharmacologic and psychotherapeutic issues in coexistent paranoid schizophrenia and narcolepsy: case report. J Clin Psychiat 1985; 46:191-3.
29. Wing YK, Lee S, Chiu HF, Ho CK, Chen CN. A patient with coexisting narcolepsy and morbid jealousy showing favorable response to fluoxetine. Postgrad Med J 1994;70:34-6.
30. Elia J, Borcherding BG, Rapoport JL, Keyson CS. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiat Res 1991;36:141-55.
31. Pelham WE, Greenslade KE, Vodde-Hamilton M, et al. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 1990;86:226-37.
32. Cole JO, Boling LA, Beake BJ. Stimulant drugs - medical needs, alternate indications, and related problems. In: Cooper JR, Czechowicz DJ, Molinari SP, Petersen RC, eds. Impact of prescription drug diversion control systems on medical practice and patient care. NIDA Res. Monogr. No. 131. NIH Publ. No. 93-3507. Washington, DC: U.S. Department of Health and Human Services, 1993:89-108.
33. Owens NJ, Larrat EP, Fretwell MD. Improving compliance in the older patient. In: Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991:107-19.
34. Melnikow J, Kiefe C. Patient compliance and medical research: issues in methodology. J Gen Int Med 1994;9:96-105.
35. Steiner JF, Fihn SD, Blair B, Inui TS. Appropriate reductions in compliance among well-controlled hypertensive patients. J Clin Epidemiol 1991;44:1361-71.
36. Mitler MM, Erman M, Hajdukovic R. The treatment of excessive somnolence with stimulant drugs. Sleep 1993;16:203-6.
37. Parkes JD, Dahlitz M. Amphetamine prescription. Sleep 1993; 16:201-3.
38. Piscopo JA. Impact of drug regulation and diversion control system on legitimate narcolepsy patients. In: Cooper JR, Czechowicz DJ, Molinari SP, Petersen RC, eds. Impact of prescription drug diversion control systems on medical practice and patient care. NIDA Res. Monogr. No. 131. NIH Publ. No. 93-3507. Washington, DC: U.S. Department of Health and Human Services, 1993:249-59.
39. Rogers AE. Problems and coping strategies identified by narcoleptic subjects. J Neurosurg Nurs 1984;16:326-34.
40. Alaia SL. Life effects of narcolepsy: measures of negative impact, social support and psychological well-being. Loss, Grief, Care 1992;5:1-22.
41. Kirkland L. Narcolepsy - attitudes and amphetamines. (Letter and comments.) Hosp Pract 1991;26 (2A):12.